# reload+after+2024-01-21 12:47:18.553812
address1§2 Corporate Drive
address2§First Floor
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 239 2030
website§https://www.sentibio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
fullTimeEmployees§122
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Timothy K. Lu M.D., Ph.D.', 'age': 42, 'title': 'Co-founder, CEO, President & Director', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 811262, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James J. Collins Ph.D.', 'age': 57, 'title': 'Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 41492, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Deborah A. Knobelman Ph.D.', 'age': 49, 'title': 'CFO, Head of Corporate Development & Treasurer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 600217, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Susan D. Berland', 'age': 68, 'title': 'Senior Financial Executive & Independent Director', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 54229, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kanya  Rajangam M.D., Ph.D.', 'age': 50, 'title': 'Head of Research & Development and Chief Medical Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 679708, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Wilson  Wong Ph.D.', 'title': 'Scientific Co-Founder & Member of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mike  Rhee', 'title': 'Senior VP of Legal Affairs & Corporate Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Susan  Kahlert', 'title': 'Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§3.121
priceToSalesTrailing12Months§10.371211
currency§USD
dateShortInterest§1702598400
forwardEps§-0.75
exchange§NGM
quoteType§EQUITY
shortName§Senti Biosciences, Inc.
longName§Senti Biosciences, Inc.
firstTradeDateEpochUtc§1622035800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§6e1c0497-dfb2-3427-8088-6f54c5e467cc
gmtOffSetMilliseconds§-18000000
targetHighPrice§6.0
targetLowPrice§6.0
targetMeanPrice§6.0
targetMedianPrice§6.0
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§1
quickRatio§5.804
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
